D rug-eluting stents (DES) that deliver antiproliferative drugs from a durable polymer have significantly reduced restenosis compared with bare metal stents. 1 However, durable polymers may be associated with inflammation, delayed healing, and incomplete endothelialization, which may contribute to the risk of late (30 days to 1 year) and very late (>1 year) stent thrombosis compared with bare metal stents. 2 Whether metal alloy coronary stent platforms with bioresorbable polymers are associated with improved clinical outcomes when compared with newer durable polymer DES has been the subject of debate 3,4 and may be influenced by additional factors, including stent strut thickness, polymer composition, distribution, and load. 5 Although current American College of Cardiology/ American Heart of Association (ACC/AHA) clinical practice guidelines recommend at least 12 months of dual antiplatelet therapy (DAPT) after DES deployment in patients who are not at increased risk for bleeding, 1 recent studies suggest that even longer duration DAPT therapy (≥30 months) provides Background-Drug eluting stents with durable polymers may be associated with hypersensitivity, delayed healing, and incomplete endothelialization, which may contribute to late/very late stent thrombosis and the need for prolonged dual antiplatelet therapy. Bioabsorbable polymers may facilitate stent healing, thus enhancing clinical safety. The SYNERGY stent is a thin-strut, platinum chromium metal alloy platform with an ultrathin bioabsorbable Poly(D,L-lactide-co-glycolide) abluminal everolimus-eluting polymer. We performed a multicenter, randomized controlled trial for regulatory approval to determine noninferiority of the SYNERGY stent to the durable polymer PROMUS Element Plus everolimus-eluting stent. Methods and Results-Patients (n=1684) scheduled to undergo percutaneous coronary intervention for non-ST-segmentelevation acute coronary syndrome or stable coronary artery disease were randomized to receive either the SYNERGY stent or the PROMUS Element Plus stent. The primary end point of 12-month target lesion failure was observed in 6.7% of SYNERGY and 6.5% PROMUS Element Plus treated subjects by intention-to-treat (P=0.83 for difference; P=0.0005 for noninferiority), and 6.4% in both the groups by per-protocol analysis (P=0.0003 for noninferiority). Clinically indicated revascularization of the target lesion or definite/probable stent thrombosis were observed in 2.6% versus 1.7% (P=0.21) and 0.4% versus 0.6% (P=0.50) of SYNERGY versus PROMUS Element Plus-treated subjects, respectively. Conclusions-In this randomized trial, the SYNERGY bioabsorbable polymer everolimus-eluting stent was noninferior to the PROMUS Element Plus everolimus-eluting stent with respect to 1-year target lesion failure. These data support the relative safety and efficacy of SYNERGY in a broad range of patients undergoing percutaneous coronary intervention. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01665053.
EVOLVE II 12-Month Primary End Point additional ischemic event reduction. 6 The SYNERGY stent (Boston Scientific Corporation, Marlborough, MA) is a novel thin-strut platinum chromium (PtCr) metal alloy stent that elutes everolimus from an ultrathin bioabsorbable Poly(D,Llactide-co-glycolide) polymer applied to the abluminal surface.
The EVOLVE randomized controlled trial (EVOLVE: A Prospective Randomized Multicenter Single-blind Noninferiority Trial to Assess the Safety and Performance of the Evolution Everolimus-Eluting Monorail Coronary Stent System [Evolution Stent System] for the Treatment of a De novo Atherosclerotic Lesion; NCT01135225) found SYNERGY to be noninferior to the durable polymer PROMUS Element everolimus-eluting stent (EES) for the angiographic end point of in-stent late lumen loss at 6 months, 7 but lacked sufficient power to provide meaningful comparison(s) of clinical events. 8 EVOLVE II represents the pivotal, randomized controlled clinical trial evaluating the clinical efficacy and safety of the SYNERGY stent for regulatory approval in a broad population of patients undergoing percutaneous coronary intervention (PCI).
Methods
EVOLVE II is a prospective, international, multicenter, randomized (1:1 SYNERGY versus PROMUS Element Plus), controlled, singleblind, noninferiority trial (EVOLVE RCT) conducted at 125 clinical sites. EVOLVE II also includes a concurrent, nonrandomized, single-arm, pharmacokinetic substudy (EVOLVE II PK), as well as a consecutively enrolled, nonrandomized, single-arm, diabetes mellitus substudy (EVOLVE II Diabetes; Figure 1 ), both of which will be reported separately. EVOLVE II was conducted in accordance with the US Food and Drug Administration's Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance, the Declaration of Helsinki, the International Conference on Harmonisation, and all local regulations, as appropriate. Institutional Review Boards at each center approved the study protocol and all subjects provided written informed consent. The study is registered at www.clinicalTrials.gov under identifier NCT01665053.
Device Description
The SYNERGY stent is a thin-strut (74-81 μm), PtCr metal alloy platform with an ultrathin (4 μmol/L) bioabsorbable Poly(D,Llactide-co-glycolide) abluminal polymer, which elutes everolimus (100 μg/cm 2 ). SYNERGY has been compared with the durable polymer PROMUS Element EES as described previously 9, 10 (Table 1) .
Study Design and Procedure
Eligible patients were aged ≥18 years and had either symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia. Stents were implanted for treatment of ≤3 (maximum) discrete target lesions in ≤2 (maximum) 2 major epicardial vessels with lesion length ≤34 mm and reference vessel diameter ≥2.25 to ≤4.0 mm. Target stenoses were ≥50% and <100% with thrombolysis in myocardial infarction flow >1. Subjects were required to have either target stenosis ≥70% or a stenosis ≥50% to <70% with abnormal fractional flow reserve, elevated cardiac biomarkers, or objective evidence of myocardial ischemia (abnormal stress or imaging stress test). Patients with recent ST-segment-elevation myocardial infarction, left main disease, chronic total occlusions, vein graft disease, or
WHAT IS KNOWN
• Durable polymer on coronary drug-eluting stents may be associated with inflammation, neoatherosclerosis, and thrombosis.
• Bioabsorbable polymers may facilitate healing and enhanced clinical safety.
WHAT THE STUDY ADDS
• In a prospective, multicenter randomized singleblind trial, the Synergy stent, with a bioabsorbable polymer, proved noninferior to the PROMUS Element Plus stent for target lesion failure to 1 year.
• This study establishes comparable clinical safety and efficacy of everolimus elution from a bioabsorbable polymer thin strut platinum chromium metal platform in support of regulatory approval for this novel coronary stent device. in-stent restenosis were excluded per-protocol. Subjects who satisfied study selection criteria were randomly assigned 1:1 (stratified by diabetic status and enrollment site) to receive treatment with either SYNERGY or PROMUS Element Plus stents. Random permuted blocks were used to ensure approximate balance of treatment allocation within each stratum. EVOLVE II RCT is a single blind trial; subjects were blinded to treatment assigned and treatment received and will remain blinded until after trial completion. Packaging of the investigational control and test devices was different, therefore, the investigator performing the procedure was not blinded to the assigned treatment arm or resulting treatment. Site personnel conducting clinical follow-up, core laboratory personnel and the Clinical Events Committee were blinded to patient treatment assignment during the trial.
DAPT with aspirin and a P2Y 12 inhibitor was prescribed after PCI for at least 6 months (12 months in patients not at high risk of bleeding). An independent core laboratory evaluated all baseline and repeat angiograms (Beth Israel Deaconess Medical Center, Boston, MA). Clinical follow-up was required in-hospital at 30 days, 6, 12, and 18 months after PCI then annually between 2 and 5 years. There was no protocol-specified coronary angiography in follow-up.
End Points
The primary end point for EVOLVE II was the rate of 12-month target lesion failure (TLF), defined as the composite occurrence of any ischemia-driven revascularization of the target lesion, myocardial infarction (MI) related to the target vessel, or any cardiac death. Secondary clinical end points included individual components of TLF; target vessel failure defined as the composite occurrence of ischemia-driven target vessel revascularization, MI related to the target vessel or cardiac death related to the target vessel), all-cause death, and stent thrombosis (defined by the Academic Research Consortium; ST). 11 All major adverse events were adjudicated by a Clinical Events Committee and the decisions of the Clinical Events Committee superseded those of the investigational center in the event of a disparity. Spontaneous MI was defined as the rise and fall of cardiac biomarkers with ≥1 value >99th percentile of the upper reference limit with evidence of myocardial ischemia. The diagnosis of periprocedural MI required at least 1 of the following: (1) CK-MB >3× upper reference limit without clinical or imaging correlates, (2) new pathological Q waves, or (3) autopsy evidence of acute MI. MI was also independently assessed by Academic Research Consortium criteria as a secondary analysis. 11 Further details pertaining to the definition of MI are found in the Data Supplement document. Technical success was defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization with postprocedure diameter stenosis of <30% and thrombolysis in myocardial infarction 3 flow in the target lesion (as visually assessed by the treating physician). Clinical procedural success was defined as postprocedure diameter stenosis <30%, thrombolysis in myocardial infarction 3 flow in all target lesions and the absence of in-hospital MI, TVR, or cardiac death. All procedural and follow-up (through 12 months) angiograms were systematically evaluated for longitudinal stent deformation by the independent angiographic core laboratory.
Statistical Methods
The study primary end point, powered for noninferiority, was the rate of 12-month TLF. 
Results

Patients and Enrollment
Between November 2012 and August 2013, 1684 patients were enrolled and randomized at 125 sites in North America, Europe, Australia, New Zealand, Japan, and Singapore. Of these, 846 were randomized to SYNERGY and 838 to PRO-MUS Element Plus (Figure 1 ). One-year follow-up was available in 831 (98.2%) SYNERGY and 806 (96.2%) PROMUS Element Plus stent-treated patients. (Tables 2 and 3 ). The average age was 64 years, 31% of subjects had medically treated diabetes mellitus, more than a third had unstable angina, and more than quarter had MI diagnosed before the index PCI ( Table 2 ). More than 20% of patients in each treatment group had multilesion (≥2 lesion) PCI and ≈75% of target lesions were classified as AHA/ACC B2/C lesion complexity (Table 3) by core laboratory adjudicated quantitative coronary angiography. Procedural characteristics (Table 4 ) and postprocedural angiographic results (Table 5 ) were similar between treatment groups with the exception that site-reported technical success was more frequent among SYNERGY-treated patients (98.3% SYNERGY versus 96.9% PROMUS Element Plus; P=0.04). Two instances of longitudinal stent deformation were observed through 12 months, both of which involved PROMUS Element Plus Stents; 1 in the PROMUS Element Plus arm and 1 in the SYNERGY arm (occurring in a PROMUS Element Plus stent mistakenly used during the index procedure). Compliance with DAPT to 6 and 12 months was 97.7% and 89.7% for SYNERGY and 96.9% and 87.3% for PROMUS Element Plus with no significant differences between stent types.
Primary End Point Analyses
The trial primary end point of TLF analyzed by intentionto-treat was observed in 6.7% of SYNERGY and 6.5% of PROMUS Element Plus-treated patients (1-sided 97.5% Farrington-Manning upper confidence bound of 2.68%) P=0.0005 noninferiority (Figure 2 ). Per-protocol analysis demonstrated TLF to be 6.4% in each treatment group (upper confidence bound, 2.51%; P=0.0003 for noninferiority). Because both intention-to-treat and per-protocol analyses demonstrate P<0.025, the SYNERGY stent is determined to (MI; B) , and clinically indicated revascularization of the target lesion (TLR; C). Event rate±1.5 SE; P value from a log-rank test. EVOLVE II 12-Month Primary End Point be noninferior to the PROMUS Element Plus stent for TLF at 1 year. Kaplan-Meier curves for TLF event rate occurrence over time were similar for both the stents (Figure 3) , as were the individual components of TLF (Figure 4 ). Revascularization event rates to 1 year were similar between stent platforms as well (Table 6 ). There were 3 definite/probable STs in the SYNERGY arm (0.4%) and 5 in the PROMUS Element Plus arm (0.6%; P=0.50). The 2 definite STs in the SYNERGY arm were acute (≤24 hours) and the 1 probable ST was subacute (6 days) postprocedure. One of the SYNERGY acute ST events involved a patient who was not treated with preprocedural aspirin. All the 5 definite/probable STs in the PROMUS Element Plus arm occurred subacutely (between 2 and 30 days; Figure 5 ).
Discussion
In this pivotal trial designed to support regulatory approval of the first bioabsorbable polymer DES available in the United States, the SYNERGY stent proved to be noninferior to the PROMUS Element Plus stent for TLF at 1 year. Furthermore, rates of target vessel MI, clinically indicated/ischemia-driven revascularization of the target lesion and stent thrombosis to 1 year were low and similar for both stents.
These clinical observations complement the finding of noninferiority of SYNERGY (versus PROMUS Element) for quantitative coronary angiographic late lumen loss (0.10 versus 0.15 mm, respectively) at 6 months reported from the EVOLVE randomized first human use trial, and provide adequate sample size from which to make more definitive conclusions about important clinical outcomes. 7, 8 In this regard, EVOLVE II supports the premise that the safety and efficacy of SYNERGY are at least comparable to the predicate PtCr durable polymer EES.
Although polymer provides a reservoir for programmed drug release, it has no function after drug release is complete and may affect the late/very late safety and efficacy of DES. First generation DES polymers (EVA-BMA [SurModics, Minneapolis, MN] and SIBS-translute [Boston Scientific]) were, at times, associated with inflammation, foreign body giant cell reaction, negative vessel remodeling, and late (acquired) stent malapposition with thrombus formation. 2, 12, 13 Durable polymers may also contribute to delayed/incomplete endothelial coverage and impaired stent healing. 2, 14 Although newer durable polymers may have enhanced biocompatibility and seem to be associated with improved clinical outcomes, they have still been incriminated in the occurrence of inflammation, neoatherosclerosis, and thrombosis. 15, 16 Indeed, neoatherosclerosis occurs earlier and with increased prevalence after DES compared with bare metal stents and has been observed with similar frequency among both first as well as newer generation DES. 17 Early randomized controlled clinical trials as well as meta-analyses suggested that biodegradable polymer DES were associated with lower rates of late/very late stent thrombosis when compared with either first generation DES or bare metal stents. 4, 18 Conversely, more recent network meta-analyses and observational studies have suggested that the newer generation cobalt chromium (CoCr) and PtCr durable polymer (polyvinylidene fluoride) EES are associated with even lower rates of stent thrombosis when compared with other durable polymer DES, early biodegradable polymer DES, and even bare metal stents. 3, [19] [20] [21] Furthermore, a randomized controlled clinical trial comparing the CoCr EES with its corresponding bare metal stent platform demonstrated lower rates of stent thrombosis at 1 and 2 years after primary PCI for ST-elevation MI in the CoCr EES group. 21 These observations are consistent with bench and preclinical data, which suggest that the durable polyvinylidene fluoride polymer may be thromboprotective against stent thrombosis. 22 Finally, a large-scale randomized controlled trial comparison of the CoCr EES versus the Nobori biodegradable polymer DES demonstrated similar long-term outcomes for both the stents. 23 These apparent inconsistencies may, at least in part, be explained by differences in biodegradable polymer DES platform design.
Both the time course and extent of endothelial stent coverage, as well as the function and maturation of endothelial cells may be influenced by multiple factors, including metal alloy, stent strut thickness, polymer composition, and distribution as well as the time course for polymer bioresorption. 5, 24, 25 In this regard, the SYNERGY stent was designed to enhance/expedite stent healing in hopes of improving clinical outcomes by incorporating thin (74 μm) PtCr struts with an ultrathin (4 μm) Poly(D,L-lactide-co-glycolide) everolimus-eluting polymer applied only to the abluminal stent surface and which is resorbed within 4 months. 7, 26 The bare metal PtCr platform which remains after polymer resorption may be less proinflammatory in cell assay when compared with gold, CoCr, or cobalt nickel alloy platforms, and seems to both expedite endothelial cell stent coverage and reduce platelet adhesion when compared with PtCr covered by polyvinylidene fluoride durable polymer. 25 Whether these putative preclinical attributes of the SYNERGY stent may translate into clinical benefit (reduction in stent related ischemic events or the relative treatment benefit recently observed for longer-term DAPT therapy 6 ) will require further study.
Limitations
Several potential limitations to this study deserve mention. First, because the study design was single-blind (patient), physician operators were not blinded with respect to stent type deployed. Second, EVOLVE II is not adequately powered to evaluate the individual components of TLF. Third, specific complex patient and target lesion subsets were excluded from the study (ST-segment-elevation myocardial infarction, left main or saphenous vein graft target stenosis, chronic total occlusion, in-stent restenosis). Despite the lack of all-comers inclusion criteria the study population seems to reflect current clinical PCI practice with regard to the number of lesions/ vessels undergoing PCI, target lesion length and angiographic complexity. 27 Finally, current follow-up duration is limited to only 1 year. Indeed, longer follow-up in more complex patient/lesion subsets may better differentiate between stent platforms with different structural design or polymer-healing attributes. Previous studies comparing DES with bioresorbable and durable polymers have, at times, demonstrated progressive differences in clinical outcomes >1 year. 18
Conclusions
The EVOLVE II randomized controlled trial demonstrates the SYNERGY coronary stent to be noninferior to the predicate PROMUS Element Plus stent for the occurrence of TLF at 1 year. Secondary end points, including ischemia-drivenrevascularization of the target lesion and ST, were also similar between stents. EVOLVE II establishes comparable clinical safety and efficacy of everolimus elution from a bioresorbable polymer-PtCr metal platform when compared with the established PtCr durable polymer EES. The longer-term relative efficacy and safety of SYNERGY will be evaluated in 5-year follow-up.
